European Hub for Advanced Therapies & Biomaterials
The ultimate goal of EHAB is to accelerate the delivery of innovative health techniques and products, in the area of advanced therapies/regenerative medicine and biomaterials to citizens and patients who need it. This innovative h...
The ultimate goal of EHAB is to accelerate the delivery of innovative health techniques and products, in the area of advanced therapies/regenerative medicine and biomaterials to citizens and patients who need it. This innovative healthcare should be affordable for all and improve the quality of life of patients. With Advanced Therapies & Biomaterials it will be possible to have more effective and efficient healthcare for lots of common diseases, like orthopedics, cancer or cardiovascular. Currently it is very hard to bring these techniques to the market and companies face many barriers, from production challenges to regulation. Joint action at an EU level can make the difference. Ecosystems can work together to overcome the barriers of the companies to catalyze and speed up the process of bringing innovative AT&B products to the market. The first step in creating this value chain is to capitalize and connect the assets with EU innovation ecosystems and lay the foundation for an excellent partnership from different European regions.
EHAB’s Vision is thus to strengthen the European landscape in advanced therapies and biomaterials (AT&B) by building a European interconnected value chain and powerhouse to making cell and tissue related therapies available to all European citizens, seizing opportunities in key parts of the AT&B value chain, consolidating EU assets, notably SMEs and increasing its international competitiveness.
EHAB’s Mission is to identify regional strengths, weaknesses, gaps and needs in a joint transregional AT&B value chain and to elaborate an action plan to strengthen the performance and capacity of the innovation ecosystems, their efficient interconnection and their alignment towards EU-level priorities, jointly tackling challenges at EU, national and regional level together with the quadruple helix stakeholders from the deeptech SME community, funding agencies, investors, academia, service providers, notified bodies, policy makers, patients.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.